Engineering Immunity for Broad Protection Against Betacoronaviruses
Document text
Principal Investigator: Emily Happy Miller Organization: ALBERT EINSTEIN COLLEGE OF MEDICINE Fiscal Year: 2024 Award: $199,584 Funding agency: National Institute of Allergy and Infectious Diseases Abstract In the past decade three highly virulent human betacoronaviruses have emerged, including SARS-CoV-2 which has caused a devastating pandemic and is responsible for the deaths of over 6 million people worldwide. Current vaccines and monoclonal antibody (mAb) treatments for SARS-CoV-2 are susceptible to mutations in the virus which can lead to decreased efficacy of these therapies. Two other highly pathogenic human betacoronaviruses, SARS-CoV and MERS-CoV, have no approved vaccines or therapeutics. There is an urgent need for broadly acting antibodies and vaccines which can protect against new variants of SARS-CoV-2 or future emerging human betacoronaviruses. Our current vaccines and mAbs for SARS-CoV-2 target the viral spike protein. The spike (S) is necessary and sufficient to mediate entry of the virus into host cells. S is comprised of two subunits. S1 is the receptor binding subunit and a major target of antibodies produced by current vaccines and mAb therapies. S2 is the membrane fusion subunit and is highly conserved among betacoronaviruses. Little is known about S2 targeting antibodies and their potential use in protecting against betacoronavirus infections. In this project we will identify and design broadly acting S2 antibodies as well as investigate Fc-effector functions of these antibodies. A multipronged approach using neutralization assays, in vitro Fc-effector function assays and systems serology will evaluate the functional properties of S2 antibodies from mice immunized with S2 immunogens. Using a panel of replication competent vesicular stomatitis virus (rVSV) pseudotype viruses expressing the spike protein from a wide range of betacoronaviruses (rVSV-CoVs) we will be able to identify antibodies that are broadly acting. Finally, by using what we learn in our analysis of endogenously produced S2 antibodies we will design bispecific S2 targeting antibodies to develop novel therapeutics broadly targeting betacoronaviruses. This project will significantly add to our knowledge of the role S2 antibodies play in infection with betacoronaviruses and how these antibodies can be utilized for future pandemic preparedness. Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><Ab-dependent cellular cytotoxicity><Ab-mediated immunity><Ab-mediated protection><Adaptive Immune System><Animals><Antibodies><Antibody Response><Antibody Therapy><Antibody immunity><Antibody protection><Antibody-mediated protection><Antigenic Determinants><Antigens><Assay><Bats><Bi-specific antibodies><Bifunctional Antibodies><Binding><Binding Determinants><Bioassay><Biological Assay><Bispecific Antibodies><C-Peptide><COVID-19 antibody><COVID-19 predisposition><COVID-19 susceptibility><COVID-19 therapy><COVID-19 treatment><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 vulnerability><COVID19 virus><Cell Body><Cells><Cessation of life><Chiroptera><Clinical Treatment Moab><CoV emergence><CoV-2><CoV2><Complement-Dependent Cytotoxicity><Coronaviridae><Coronavirus><Coronavirus disease 2019 predisposition><Coronavirus disease 2019 susceptibility><Coronavirus disease 2019 vulnerability><Data><Death><Development><Effectiveness><Engineering><Epitopes><Foundations><Future><Genetic Alteration><Genetic Change><Genetic defect><Glycoproteins><Goals><Habitats><Health><Hu-mABs><Human><Immune response><Immunity><Immunization><Immunize><Immunological response><In Vitro><Infection><Innate Immune System><Knowledge><Learning><Length><Link><MERS corona virus><MERS coronavirus><MERS virus><MERS-CoV><Mediating><Membrane Fusion><Mice><Mice Mammals><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome-CoV><Middle East Respiratory Virus><Middle East Respiratory coronavirus><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome-CoV><Modern Man><Molecular Interaction><Monoclonal Antibodies><Monoclonal Antibody Therapy><Murine><Mus><Mutation><Pathogenicity><Persons><Play><Population Growth><Predisposed to COVID-19><Predisposed to SARS-CoV-2><Predisposed to Severe acute respiratory syndrome coronavirus 2><Property><Proteins><Risk><Role><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 antibody><SARS-CoV-2 predisposition><SARS-CoV-2 susceptibility><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV-2 vulnerability><SARS-CoV2><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Scientist><Serology><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 predisposition><Severe acute respiratory syndrome coronavirus 2 susceptibility><Severe acute respiratory syndrome coronavirus 2 vulnerability><Severe acute respiratory syndrome related corona virus 2><System><Testing><Therapeutic><Therapeutic antibodies><Training><Treatment Efficacy><VAC-TX><VSV><Vaccination><Vaccine Therapy><Vaccines><Vesicular Stomatitis Virus><Vesicular stomatitis Indiana virus><Viral><Viral Diseases><Virulent><Virus><Virus Diseases><Wuhan coronavirus><acquired immune system><antibody against COVID-19><antibody against SARS-CoV-2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody assay><antibody based test><antibody based therapies><antibody dependent cell mediated cytotoxicity><antibody dependent cytotoxicity><antibody engineering><antibody mediated cellular cytotoxicity><antibody test><antibody to COVID-19><antibody to SARS-CoV-2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><antibody treatment><antibody-based therapeutics><antibody-based treatment><antibody-dependent cell cytotoxicity><antibody-dependent cellular cytotoxicity><antibody-dependent cellular phagocytosis><antibody-mediated cytotoxicity><antibody-mediated immunity><beta CoV><beta coronavirus><betaCoV><betacoronavirus><block viral entry><bsAb><career><climate change><climatic changes><combat><complement-mediated cytotoxicity><connecting peptide><corona virus><corona virus emergence><coronavirus disease 2019 antibody><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease-19 virus><coronavirus emergence><cross immunity><cross protection><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><future pandemic><genome mutation><global climate change><hCoV19><host response><humAbs><human mAbs><human monoclonal antibodies><human monoclonals><immune system response><immunogen><immunogenic><immunoresponse><inhibit viral entry><inhibitor><intervention efficacy><land use><mAB-based therapy><mAb therapy><mAb-based therapeutics><mAbs><monoclonal Abs><nCoV><nCoV2><neutralizing antibody><new CoV><new approaches><new corona virus><new coronavirus><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><next pandemic><novel><novel CoV><novel approaches><novel corona virus><novel coronavirus><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel strategies><novel strategy><novel therapeutics><novel therapy><pandemic><pandemic disease><pandemic disease preparedness><pandemic planning><pandemic preparedness><pandemic readiness><pathogen><pathogenic virus><predisposed to Coronavirus disease 2019><prevent><preventing><receptor binding><receptor bound><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe acute respiratory syndrome-CoV><social role><susceptible to COVID-19><susceptible to Coronavirus disease 2019><susceptible to SARS-CoV-2><susceptible to Severe acute respiratory syndrome coronavirus 2><therapeutic efficacy><therapeutic target><therapeutic vaccination><therapy efficacy><tool><treat COVID-19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><vaccine antibodies><vaccine development><vaccine induced antibodies><vaccine-induced antibodies><viral entry blocker><viral entry inhibitor><viral infection><viral pathogen><virus infection><virus pathogen><virus-induced disease><vulnerable to COVID-19><vulnerable to Coronavirus disease 2019><vulnerable to SARS-CoV-2><vulnerable to Severe acute respiratory syndrome coronavirus 2><β CoV><β coronavirus><βCoV>